MX349239B - Sistema de cest que muestran una sensibilidad independiente de la concentración. - Google Patents

Sistema de cest que muestran una sensibilidad independiente de la concentración.

Info

Publication number
MX349239B
MX349239B MX2013004825A MX2013004825A MX349239B MX 349239 B MX349239 B MX 349239B MX 2013004825 A MX2013004825 A MX 2013004825A MX 2013004825 A MX2013004825 A MX 2013004825A MX 349239 B MX349239 B MX 349239B
Authority
MX
Mexico
Prior art keywords
cest
concentration independent
systems exhibiting
nmr
responsiveness
Prior art date
Application number
MX2013004825A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004825A (es
Inventor
Uggeri Fulvio
Aime Silvio
Delli Castelli Daniela
Terreno Enzo
Livio Longo Dario
Fedeli Franco
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of MX2013004825A publication Critical patent/MX2013004825A/es
Publication of MX349239B publication Critical patent/MX349239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
MX2013004825A 2010-11-05 2011-11-04 Sistema de cest que muestran una sensibilidad independiente de la concentración. MX349239B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190161A EP2457594A1 (en) 2010-11-05 2010-11-05 Cest systems exhibiting a concentration independent responsiveness
PCT/EP2011/069406 WO2012059576A1 (en) 2010-11-05 2011-11-04 Cest systems exhibiting a concentration independent responsiveness

Publications (2)

Publication Number Publication Date
MX2013004825A MX2013004825A (es) 2013-06-03
MX349239B true MX349239B (es) 2017-07-18

Family

ID=43530158

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004825A MX349239B (es) 2010-11-05 2011-11-04 Sistema de cest que muestran una sensibilidad independiente de la concentración.

Country Status (11)

Country Link
US (2) US10232060B2 (enExample)
EP (2) EP2457594A1 (enExample)
JP (2) JP2013542948A (enExample)
KR (1) KR20130138807A (enExample)
CN (1) CN103260652B (enExample)
AU (1) AU2011325112B2 (enExample)
CA (1) CA2816948C (enExample)
IL (1) IL226123A (enExample)
MX (1) MX349239B (enExample)
RU (1) RU2605823C2 (enExample)
WO (1) WO2012059576A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165775A1 (en) 2013-04-05 2014-10-09 The Trustees Of The University Of Pennsylvania Magnetic resonance imaging of poly-l-glutamate
KR101653064B1 (ko) * 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법
WO2016123446A1 (en) * 2015-01-30 2016-08-04 The Johns Hopkins University Label-free mr imaging of tumor malignancy
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
HUE060536T2 (hu) * 2015-12-10 2023-03-28 Bracco Imaging Spa Dimer kontrasztanyagok
EP3394627B1 (en) * 2015-12-23 2020-06-03 Bracco Imaging S.p.A Ratiometric pulsed cest imaging
EP3544964B1 (en) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN108047151B (zh) * 2018-01-03 2020-08-04 广州康瑞泰药业有限公司 一种高收率钆布醇的制备方法
IL321215B2 (en) * 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
US12226494B2 (en) 2018-12-18 2025-02-18 Bracco Imaging S.P.A. Pharmaceutical compositions comprising Gd-complexes and polyarylene additives
US20200397924A1 (en) * 2019-01-28 2020-12-24 Hubei Tianshu Pharmaceutical Co., Ltd Preparation method of intermediate of gadolinium-based ionic contrast agent and use thereof
US12529739B2 (en) * 2022-07-26 2026-01-20 Canon Medical Systems Corporation pH calculating apparatus, magnetic resonance imaging apparatus, and pH calculating method
CN120609858A (zh) * 2025-05-30 2025-09-09 中国科学院精密测量科学与技术创新研究院 镧系金属配合物作为31p cest高场造影剂在识别atp中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9504910D0 (en) 1995-03-10 1995-04-26 Nycomed Imaging As Compounds
AU4656400A (en) 1999-04-21 2000-11-17 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method for enhancing contrast produced by mri
EP1390079A2 (en) * 2000-11-20 2004-02-25 Board of Regents University of Texas System Paramagnetic metal ion-based macrocylic contrast agents
EP1331012A1 (en) 2002-01-29 2003-07-30 BRACCO IMAGING S.p.A. Responsive paramagnetic MRI contrast agents
EP1466629A1 (en) * 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for "CEST" applications
JP2008513533A (ja) * 2004-09-23 2008-05-01 ゲルベ Ｃｅｓｔイメージング用の造影剤封入システム
RU2446829C2 (ru) * 2006-06-09 2012-04-10 Конинклейке Филипс Электроникс Н.В. Устранение зависимости от концентрации контрастного агента в мрт
EP2067485A1 (en) * 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
US20100247445A1 (en) * 2007-12-07 2010-09-30 Koninklijke Philips Electronics N.V. Polymeric drug carrier for image-guided delivery

Also Published As

Publication number Publication date
JP2017078080A (ja) 2017-04-27
IL226123A0 (en) 2013-06-27
US10232060B2 (en) 2019-03-19
IL226123A (en) 2016-02-29
WO2012059576A1 (en) 2012-05-10
US10328162B1 (en) 2019-06-25
US20130195768A1 (en) 2013-08-01
CN103260652B (zh) 2016-10-12
MX2013004825A (es) 2013-06-03
CA2816948C (en) 2016-04-05
KR20130138807A (ko) 2013-12-19
US20190209713A1 (en) 2019-07-11
AU2011325112A1 (en) 2013-05-02
EP2635311A1 (en) 2013-09-11
EP2635311B1 (en) 2017-08-16
RU2605823C2 (ru) 2016-12-27
CA2816948A1 (en) 2012-05-10
EP2457594A1 (en) 2012-05-30
RU2013125778A (ru) 2014-12-10
JP6542748B2 (ja) 2019-07-10
JP2013542948A (ja) 2013-11-28
CN103260652A (zh) 2013-08-21
AU2011325112B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
WO2011153370A3 (en) Position determination using measurements from past and present epochs
CY1119345T1 (el) Μακροκυκλικες ενωσεις ως αναστολεις κινασης trk
GEP20207146B (en) New gadolinium chelate compounds for use in magnetic resonance imaging
BR112014017169A8 (pt) máquina de bebidas com módulo removível
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
GB201004200D0 (en) Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
PT2647707T (pt) Agente terapêutico indutor de toxicidade
ECSP12012213A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos ? 2 y como antagonistas muscarinicos m3
ECSP14013327A (es) Compuestos con actividad nematicida
MX382868B (es) Composiciones que comprenden polietilenglicol y ascorbato.
MX2012007041A (es) Quelados de manganeso y su uso como agentes de contraste en elaboracion de imagen de resonancia magnetica (mri).
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
MX2014002682A (es) Modulares de la fosfodiesterasa 10 (pde 10).
PH12016500249B1 (en) Diazacarbazole derivatives as tau-pet-ligands
WO2012158467A3 (en) Indicators for detecting the presence of metabolic by-products from microorganisms
TN2013000283A1 (en) Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
MX2011012688A (es) Composicion de sal no aglutinante, proceso de preparacion y uso de la misma.
GB2517345A (en) Anthracenyl-tetralactam macrocycles and their use in detecting a target saccharide
EP2587997A4 (en) FABRIC INDICATOR DETERMINATION
IN2015DN00085A (enExample)
IT1402938B1 (it) Attrezzatura per banchi di prova dell'impianto frenante di veicoli
CY1113338T1 (el) Νεα μεθοδος για συνθεση ιβαμπραδινης και αλατων προσθηκης αυτης
MX2014002407A (es) Plataforma de bobina de recepcion de resonancia magnetica con engranaje selectivo entre la bobina de recepcion y la superficie de la mesa del paciente.
SG179067A1 (en) 13c-mr detection using hyperpolarised 13c-fructose

Legal Events

Date Code Title Description
FG Grant or registration